 Anosheh Afghahi
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 15 | 2025 | 2393 | 1.630 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2018 | 218 | 1.260 |
Why?
| | BRCA2 Protein | 4 | 2024 | 68 | 0.880 |
Why?
| | BRCA1 Protein | 4 | 2024 | 82 | 0.880 |
Why?
| | Cancer Survivors | 3 | 2025 | 338 | 0.720 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.650 |
Why?
| | Sexual Health | 1 | 2020 | 68 | 0.580 |
Why?
| | Lymphocyte Count | 1 | 2018 | 165 | 0.530 |
Why?
| | Genetic Testing | 2 | 2017 | 483 | 0.500 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1329 | 0.490 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 61 | 0.440 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 166 | 0.430 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 188 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1150 | 0.390 |
Why?
| | Genomics | 2 | 2016 | 830 | 0.390 |
Why?
| | Germ-Line Mutation | 3 | 2019 | 177 | 0.370 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 441 | 0.360 |
Why?
| | Resistance Training | 2 | 2025 | 186 | 0.330 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2399 | 0.330 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1777 | 0.290 |
Why?
| | Appetite | 2 | 2025 | 80 | 0.260 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2219 | 0.250 |
Why?
| | Genes, BRCA1 | 2 | 2017 | 45 | 0.250 |
Why?
| | SEER Program | 2 | 2018 | 230 | 0.240 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 134 | 0.230 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1475 | 0.220 |
Why?
| | Energy Intake | 2 | 2025 | 512 | 0.220 |
Why?
| | Middle Aged | 16 | 2026 | 36309 | 0.220 |
Why?
| | Eligibility Determination | 1 | 2025 | 72 | 0.210 |
Why?
| | Female | 22 | 2026 | 79045 | 0.200 |
Why?
| | Oligopeptides | 1 | 2025 | 267 | 0.190 |
Why?
| | Mutation | 5 | 2026 | 4090 | 0.190 |
Why?
| | Aged | 10 | 2026 | 26217 | 0.180 |
Why?
| | Amyloidosis | 2 | 2013 | 45 | 0.180 |
Why?
| | Carcinoma, Renal Cell | 1 | 2025 | 230 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 46 | 0.180 |
Why?
| | Humans | 25 | 2026 | 145783 | 0.180 |
Why?
| | Quality of Life | 3 | 2025 | 3211 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 2 | 2026 | 981 | 0.170 |
Why?
| | Prophylactic Mastectomy | 1 | 2021 | 10 | 0.170 |
Why?
| | Multiple Myeloma | 1 | 2025 | 309 | 0.170 |
Why?
| | Chemoprevention | 1 | 2021 | 92 | 0.160 |
Why?
| | Kidney Neoplasms | 1 | 2025 | 415 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 498 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1062 | 0.150 |
Why?
| | Neoplasms | 1 | 2015 | 2913 | 0.150 |
Why?
| | Adult | 11 | 2026 | 40881 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2026 | 688 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 596 | 0.140 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 53 | 0.140 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 467 | 0.140 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2018 | 49 | 0.140 |
Why?
| | Carcinoma, Lobular | 1 | 2018 | 56 | 0.130 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2018 | 81 | 0.130 |
Why?
| | Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2017 | 2 | 0.130 |
Why?
| | Penetrance | 1 | 2017 | 30 | 0.130 |
Why?
| | Genes, BRCA2 | 1 | 2017 | 33 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 154 | 0.120 |
Why?
| | Platinum | 1 | 2017 | 48 | 0.120 |
Why?
| | Carboplatin | 1 | 2017 | 164 | 0.120 |
Why?
| | California | 1 | 2018 | 473 | 0.120 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 258 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1372 | 0.110 |
Why?
| | Mortality | 1 | 2018 | 381 | 0.110 |
Why?
| | Imatinib Mesylate | 1 | 2015 | 77 | 0.110 |
Why?
| | Trastuzumab | 1 | 2015 | 118 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 956 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1330 | 0.100 |
Why?
| | Neoplasm Grading | 1 | 2015 | 311 | 0.100 |
Why?
| | Peptide YY | 2 | 2025 | 28 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 328 | 0.100 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 128 | 0.100 |
Why?
| | Ghrelin | 2 | 2025 | 42 | 0.100 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 508 | 0.100 |
Why?
| | Prognosis | 2 | 2023 | 4330 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 364 | 0.100 |
Why?
| | Melphalan | 1 | 2013 | 43 | 0.100 |
Why?
| | Immunoglobulin Light Chains | 1 | 2013 | 52 | 0.100 |
Why?
| | Thalidomide | 1 | 2013 | 43 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1969 | 0.090 |
Why?
| | Disease Management | 1 | 2017 | 653 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2025 | 427 | 0.090 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 385 | 0.090 |
Why?
| | Laryngeal Diseases | 1 | 2012 | 31 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 883 | 0.080 |
Why?
| | Dexamethasone | 1 | 2013 | 365 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8347 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1507 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 668 | 0.080 |
Why?
| | Prevalence | 1 | 2017 | 2875 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 341 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 948 | 0.070 |
Why?
| | Registries | 1 | 2018 | 2410 | 0.070 |
Why?
| | Melanoma | 1 | 2015 | 762 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1477 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 853 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1202 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3752 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4302 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6085 | 0.060 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2026 | 51 | 0.060 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2026 | 72 | 0.060 |
Why?
| | Survival Rate | 2 | 2025 | 2094 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 42 | 0.050 |
Why?
| | Kidney Function Tests | 1 | 2025 | 156 | 0.050 |
Why?
| | Young Adult | 2 | 2026 | 14254 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2025 | 196 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 183 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 40 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2026 | 17330 | 0.050 |
Why?
| | Creatinine | 1 | 2025 | 515 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 55 | 0.050 |
Why?
| | Risk Factors | 1 | 2017 | 10919 | 0.050 |
Why?
| | Homologous Recombination | 1 | 2022 | 37 | 0.050 |
Why?
| | Breast | 1 | 2023 | 156 | 0.050 |
Why?
| | Phthalazines | 1 | 2022 | 63 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2668 | 0.040 |
Why?
| | Body Image | 1 | 2022 | 96 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 765 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 610 | 0.040 |
Why?
| | Mammography | 1 | 2021 | 166 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2019 | 54 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 346 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2018 | 60 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2022 | 495 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2018 | 81 | 0.030 |
Why?
| | Aminopyridines | 1 | 2018 | 129 | 0.030 |
Why?
| | Purines | 1 | 2018 | 187 | 0.030 |
Why?
| | Benzimidazoles | 1 | 2018 | 189 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11794 | 0.030 |
Why?
| | Male | 5 | 2026 | 73011 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2018 | 244 | 0.030 |
Why?
| | Mastectomy | 1 | 2018 | 185 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 680 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1378 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 375 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 688 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 404 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1261 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 609 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 963 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 923 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2012 | 121 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1043 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3551 | 0.020 |
Why?
| | Metastrongyloidea | 1 | 1969 | 1 | 0.020 |
Why?
| | Mollusca | 1 | 1969 | 6 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1082 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3916 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1512 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1898 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 6033 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18356 | 0.010 |
Why?
| | Animals | 2 | 2018 | 38102 | 0.010 |
Why?
| | Parasitic Diseases, Animal | 1 | 1969 | 6 | 0.000 |
Why?
| | Snails | 1 | 1969 | 39 | 0.000 |
Why?
| | Ecology | 1 | 1969 | 105 | 0.000 |
Why?
| | Dog Diseases | 1 | 1969 | 106 | 0.000 |
Why?
| | Dogs | 1 | 1969 | 478 | 0.000 |
Why?
| | Aging | 1 | 1969 | 1973 | 0.000 |
Why?
|
|
Afghahi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|